RayKnowChina Research Map
Shortlist

Enrolling by invitationLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Personalized SBRT in Early-Stage Peripheral NSCLC

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Tianjin Medical University Cancer Institute & Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07167459, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Pathologically confirmed non-small-cell lung cancer (NSCLC) staged T1-2N0M0 (IA-IIA, AJCC 8th ed.).

    Inclusion criterion 3

  3. Medically inoperable (e.g., FEV1 <40 % predicted, DLCO <40 % predicted, NYHA class III-IV heart failure) or refusal of surgery.

    Inclusion criterion 5

  4. ECOG performance status 0-2.

    Inclusion criterion 6

  5. Measurable disease by RECIST 1.1.

    Inclusion criterion 8

  6. Concurrent or prior malignancy within 5 years (except adequately treated basal-cell carcinoma of skin or carcinoma in situ of cervix).

    Exclusion criterion 3

  7. Effective contraception for women of child-bearing potential and fertile men for 12 months after SBRT completion.

    Inclusion criterion 11

    Pregnancy, lactation, or planned pregnancy.

    Exclusion criterion 5

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07167459, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria

  • Participant or legal guardian provides written informed consent.
  • Age ≥18 years; no upper age limit; male or female.
  • Pathologically confirmed non-small-cell lung cancer (NSCLC) staged T1-2N0M0 (IA-IIA, AJCC 8th ed.).
  • Peripheral tumor location: ≥2 cm from the proximal bronchial tree or any mediastinal structure.
  • Medically inoperable (e.g., FEV1 <40 % predicted, DLCO <40 % predicted, NYHA class III-IV heart failure) or refusal of surgery.
  • ECOG performance status 0-2.
  • Life expectancy ≥6 months per investigator judgment.
  • Measurable disease by RECIST 1.1.
  • Adequate organ function (blood counts, liver and renal indices) per institutional standards.
  • Willing and able to comply with all study procedures, imaging schedules, and follow-up visits.
  • Effective contraception for women of child-bearing potential and fertile men for 12 months after SBRT completion.

Exclusion Criteria

  • Previous thoracic radiotherapy, chemotherapy, targeted therapy, or surgery for lung cancer.
  • Evidence of regional or distant metastases.
  • Concurrent or prior malignancy within 5 years (except adequately treated basal-cell carcinoma of skin or carcinoma in situ of cervix).
  • Active interstitial pneumonitis, radiation pneumonitis, drug-induced pneumonitis, or clinically significant pulmonary fibrosis.
  • Pregnancy, lactation, or planned pregnancy.
  • Participation in another interventional clinical trial with an unmet primary endpoint.
  • Known psychiatric disorder, substance abuse, or other condition that would impair compliance.
  • Contraindication to contrast-enhanced CT or PET-CT imaging.
  • Investigator-determined medical, social, or psychological contraindications that could compromise safety or data integrity.

Quoted from ClinicalTrials.gov, NCT07167459, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07167459, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07167459